Podcasts about Tofacitinib

Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss treatment strategies for people who are immunocompromised with COVID-19 in the hospital setting, including: Antiviral therapy with remdesivirDexamethasone for patients with hematologic malignanciesConsiderations regarding other immunomodulators such as JAK inhibitors or IL-6 inhibitorsA detailed patient case to illustrate key takeaways Presenters:Michele Bartoletti, MD, PhD​Associate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), ItalyCristina Mussini, MD​Full Professor of Infectious DiseasesChief of the Department of Infectious DiseasesUniversity of Modena and Reggio EmiliaModena, ItalyMartin Witzenrath, MD, FERS Medical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benamin FranklinCharite – University of BerlinBerlin, GermanyLink to full program:https://bit.ly/4fs7HcbDownloadable slides:https://bit.ly/3XP1fpJGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss: Workup of COVID-19 in the emergency departmentMethods of COVID-19 risk stratification Treatment recommendations for people with severe COVID-19, including how to effectively use antiviral therapy, dexamethasone, and other immunomodulators[CC1] in this population A detailed patient case to illustrate key takeawaysPresenters:Stephen Cantrill, MD, FACEP​Associate Director and Medical Director (Retired) ​ Department of Emergency Medicine​ Denver Health Medical Center​ Associate Professor ​ Department of Emergency Medicine​ University of Colorado Health Sciences Center​ Denver, Colorado Rajesh T. Gandhi, MD​Massachusetts General Hospital​ Professor of Medicine​ Harvard Medical School​ Boston, Massachusetts Payal K. Patel, MD, MPH, FIDSA​Systemwide Director of Antimicrobial Stewardship​ Associate Professor, Division of Infectious Diseases​ Intermountain Health​ Salt Lake City, Utah Link to full program: https://bit.ly/4gu2gcUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss treatment strategies for people who have severe COVID-19, including: Antiviral therapy with remdesivir Dexamethasone and other systemic corticosteroids Immunomodulators, such as JAK inhibitors or IL-6 inhibitors Overviews of clinical trial data demonstrating how and when to use these therapiesPresenters:Stephen Cantrill, MD, FACEP​Associate Director and Medical Director (Retired) ​ Department of Emergency Medicine​ Denver Health Medical Center​ Associate Professor ​ Department of Emergency Medicine​ University of Colorado Health Sciences Center​ Denver, Colorado Rajesh T. Gandhi, MD​Massachusetts General Hospital​ Professor of Medicine​ Harvard Medical School​ Boston, Massachusetts Payal K. Patel, MD, MPH, FIDSA​Systemwide Director of Antimicrobial Stewardship​ Associate Professor, Division of Infectious Diseases​ Intermountain Health​ Salt Lake City, Utah Link to full program: https://bit.ly/4gu2gcUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.    

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV - Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: www.youtube.com/@dermaspherepodcast and VuMedi!: www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare - ⁠ Connect with us! - Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!

The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. Evaluating Factors Associated With Telehealth Appropriateness in Outpatient Rheumatoid Arthritis Encounters Using the Encounter Appropriateness Score for You (EASY) - doi.org/10.3899/jrheum.2024-0014 Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials - doi.org/10.3899/jrheum.2023-1198 Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept Study - doi.org/10.3899/jrheum.2024-0074 Comparison Of Attainment And Protective Effects Of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established SLE - doi.org/10.3899/jrheum.2023-0900 Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review - doi.org/10.3899/jrheum.2023-0788

Welcome back to the Evidence-Based Hair Podcast! This episode continues our June theme on JAK inhibitors, focusing on their topical use for treating frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP). We'll delve into a groundbreaking study by Dr. Maryanne Senna and colleagues from Boston, examining the effectiveness and side effects of topical 2% tofacitinib for FFA and LPP. The study's results provide encouraging data, showing that about 31.6% of patients experienced improvement, and 60.5% saw disease stabilization. Join us as we explore the potential of topical JAK inhibitors in managing scarring alopecia, their practical applications, and the implications for future treatment protocols. Don't miss our insightful discussion on this emerging therapy and how it could transform patient care. Next month, we'll shift gears to discuss spironolactone and its role in treating androgenetic hair loss in women. Stay tuned!   STUDIES REFERENCED IN THIS EPISODE Li-Chi Chen, Chino Ogbutor, Kristen J Kelley, Maryanne M Senna. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024 Jun;90(6):1260-1262. doi: 10.1016/j.jaad.2024.01.060. Epub 2024 Feb 2.   Yang C.C., Khanna T., Sallee B., Christiano A.M., Bordone L.A.: Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther 2018; 31:   Moussa A., Bhoyrul B., Asfour L., Kazmi A., Eisman S., Sinclair R.D.: Treatment of lichen planopilaris with baricitinib: a retrospective study. J Am Acad Dermatol 2022; 87: pp. 663-666.   Plante J., Eason C., Snyder A., Elston D.: Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol 2020; 83: pp. 1487-1489.

Welcome back to another episode of the Evidence-Based Hair Podcast!  In this episode, we delve into a fascinating study on the use of generic tofacitinib for treating alopecia areata. This study, published in the Archives of Dermatologic Research, explores the effectiveness and safety of generic tofacitinib. With the recent availability of this cost-effective alternative in Canada, the study provides valuable insights into whether switching from brand name options (Xeljanz) is a viable choice for patients. The retrospective study included 20 patients with advanced alopecia areata, and the results were promising. A significant number of patients experienced noticeable improvements in hair regrowth, with low incidence of side effects. This episode discusses the study's findings and the broader implications for treatment options in alopecia areata. Join me as we explore how this study might change the landscape of hair loss treatment and what it means for patients and practitioners alike. Don't miss next week's episode, where we'll discuss the use of baricitinib in young children.     STUDY REFERENCED Jian  J et al. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study. Arch Dermatol Res. 2024 May 11;316(5):154. doi: 10.1007/s00403-024-02879-4.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.

The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study - doi.org/10.3899/jrheum.2023-0721 Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs - doi.org/10.3899/jrheum.2023-0995 Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results from the CorEvitas Rheumatoid Arthritis Registry - doi.org/10.3899/jrheum.2023-0752 Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA) - doi.org/10.3899/jrheum.2023-0716 Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan - doi.org/10.3899/jrheum.2023-0867 Role of Creation of Plain Language Summaries to Disseminate COVID-19 Research Findings to Patients With Rheumatic Diseases - doi.org/10.3899/jrheum.2023-0998

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.

An Interview with Kevin Winthrop_ Three Questions About COVID 19 Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis Biologics in RA_ Mechanisms of Delivery Over Mechanisms of Action_ (1) Cannabinoid Receptor in RA Patients Impact of Tofacitinib on Skeletal Muscle in RA No Increased Mortality in Patients with RA Receiving Checkpoint Inhibitors Non-TNFi b_tsDMARDs vs. TNFi in RA-ILD Older RA Patients Just Aren't Getting Treated People with RA and Long COVID Had Worse Pre-COVID RA Symptoms Reproductive History, HPV Vaccination Among Women with SLE and  RA Teledidactic vs On Campus Training in Musculoskeletal Ultrasound The SMART Study_ Split Dose Oral Methotrexate Unravelling the Mechanism of Clots with JAK Inhibitors Upadacitinib for Pain_ Is That Real_ Will CAR T Cells also treat RA_

Another TYK2 Ticks the Boxes Head to Head Comparison of Tofacitinib and TLL-018 in RA Impact of Tofacitinib on Skeletal Muscle in RA Is Point of Care Ultrasound Hocus Pocus_ JAK1 TYK2 in RA Monitoring the Effect of Therapy with a...Smart Watch_ Non-TNFi b_tsDMARDs vs. TNFi in RA-ILD Simulated JAK Trials to Counter ORAL Survelliance Treatments in SpA Unravelling the Mechanism of Clots with JAK Inhibitors Upadacitinib for Pain_ Is That Real_

Cannabinoid Receptor in RA Patients Cardiac Troponin T and MACE Events in RA Imaging Updates in SpA Impact of Tofacitinib on Skeletal Muscle in RA Teledidactic vs On Campus Training in Musculoskeletal Ultrasound Treatments in SpA

Head to Head Comparison of Tofacitinib and TLL-018 in RA Non-TNFi b_tsDMARDs vs. TNFi in RA-ILD People with RA and Long COVID Had Worse Pre-COVID RA Symptoms Reproductive History, HPV Vaccination Among Women with SLE and  RA Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA The SMART Study_ Split Dose Oral Methotrexate Undiagnosed IBD in AxSpA Using Telemedicine to Improve Diagnosis of AxSpA Window of Opportunity in PsA

Omega-3s help isotretinoin - Covid and autoimmune disease - Transient abdominal telangiectasia of the newborn - Systemic tacrolimus in derm - MTX + prednisone for alopecia totalis/universalis - Tofacitinib for BP - Check out our video content on YouTube: https://www.youtube.com/@dermaspherepodcast and VuMedi!: https://www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠⁠https://physicians.utah.edu/echo/dermatology-primarycare - ⁠⁠Connect with us! - Web: ⁠https://dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!)

Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, is joined by Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as well as Doctor Frank Behrens, Medical director at Goethe-University. The papers covered in this topical discussion highlight two interesting areas of the modern PsA therapeutic landscape. The first of the publications discusses the safety and efficacy of upadacitinib in the treatment of patients with PsA and an inadequate response to bDMARDs through a three-year study. The second, explores an analysis of the real-world safety profile of tofacitinib in the treatment of patients with PsA. If you would like to read more about the topics discussed, head over to cytokinesignalling.com, where you'll find detailed summary slides of each of the papers.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Martin Bergman, a Clinical Associate Professor of Medicine at the Drexel University College of Medicine in Philadelphia, to discuss his recent paper ‘One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.' Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.

Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.

Dr Hudesman reviews the findings of a post hoc analysis to assess associations between C-reactive protein, partial Mayo score, and efficacy outcomes during tofacitinib induction that he and his colleagues conducted.

Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'

Join Drs Cohen and Gibofsky as they step through a case of refractory psoriatic arthritis, discuss novel therapeutics, review latest clinical trials, and talk about the future in psoriatic arthritis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970786). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis Workup https://emedicine.medscape.com/article/2196539-workup#c6 GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/49/6_Suppl_1/52.long Methotrexate in Psoriasis and Psoriatic Arthritis https://www.jrheum.org/content/96/31 Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication#4 Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients https://www.jrheum.org/content/47/6/854 Three JAK Inhibitors Get Boxed Warnings, Modified Indications https://www.medscape.com/viewarticle/958024 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340607/ Upadacitinib in Patients With Psoriatic Arthritis and an Inadequate Response to Non-biological Therapy: 56-Week Data From the Phase 3 SELECT-PsA 1 Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524381/ Multicentre, Randomised, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Naïve to Biological Disease-Modifying Antirheumatic Drug: Final Results by Week 52 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509529/ Improvement in Patient-Reported Outcomes in Patients With Psoriatic Arthritis Treated With Upadacitinib Versus Placebo or Adalimumab: Results From SELECT-PsA 1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/ Bimekizumab in Patients With Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(19)33161-7 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment https://clinicaltrials.gov/ct2/show/NCT04908189

Best of ACR Day Two in PSA Dr. Rachel Tate, discusses abstracts 1018, 1159 at ACR22 Convergence. Comorbidities in Ankylosing Spondylitis Dr. Akhil Sood discusses Abstract 1609 at ACR22 Convergence. Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at ACR22 Convergence.  Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis GCA: What we feel and what we can't Dr David Liew discusses Abstracts 0483 and 0486 at ACR22 Convergence. Hydroxychloroquine: Cumulative Doses and Thresholds Dr. Sheila Reyes discusses Abstracts 0982 and 0344 at ACR22 Convergence. JAK inhibitors in rheumatic diseases Dr. Antoni Chan discusses abstracts 0510 and 0404 at ACR22 Convergence in Philadelphia, PA. Abstract 0510: MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Abstract 0404: Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial Low-grade Proteinuria in Non-Renal Lupus: Should We be Worried? Dr. Yuz Yusof discusses Abstract 1463 presented at ACR22 Convergence in Philadelphia, PA. PET CT Imaging to Define Risk of Progression from PSO to PsA Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence. Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence.  Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes) Tapering TNF Inhib in non Radiolgraphic AxSpA Dr. Peter Nash, Philadelphia Vaccines Work! Dr. Eric Dein and Dr. Caoilfhionn Connolly discuss abstracts 2275 & 0797 at ACR22 Convergence.

Bouncebackability portends increased risk of adverse outcomes in RA Dr. Richard Conway discusses Abstract 2218 at ACR22 Convergence. Abstract 2218: Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis Deucravacitinib in PsA Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial Efficacy and Safety Results from BE OPTIMAL in PsA Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA.  L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study Hydroxychloroquine Update from ACR22 Dr. Michelle Petri reviews several abstracts presented at ACR22 Convergence. Abstracts 0343, 0538, 0976, 0983, 0981, 0980 RA: Steroids are bad, again Dr. Richard Conway discusses Abstract 2219 at ACR22 Convergence Abstract 2219: Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis Tapering TNFi in nonradiographic AxSpA Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA. Tofacitinib and RA-ILD Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence.  Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib Life or Organ Threatening SLE: What To Do? Is There Anything New? Dr. Michelle Petri discusses Abstracts 1651, 1677 at ACR22 Convergence in Philiadelphia, PA.      

During “The Great Debate” at ACR Convergence 2020, the question: “Should JAK inhibitors be started before TNF inhibitors in people with rheumatoid arthritis who failed methotrexate?” was asked. However, in 2021, results from the oral surveillance trial showed an increased risk of major adverse cardiovascular events in cancers among patients with rheumatoid arthritis taking tofacitinib as compared to those on TNF inhibitors. These findings led to the FDA updating their black box warning on JAK inhibitors. Today, we've invited one of the speakers on the great debate, Dr. Vibeke Strand, to speak on her position on JAK inhibitors given these new results and shed some more light on the subject. 

Katarzyna Pawlak talks to Dr Goessens (Belgium) about his recent paper on the efficacy and safety of combining biologic agents and small molecules in IBD, recognized with the UEG Journal 2022 Best Paper Award.

STUDIES HIGHLIGHTED IN THIS EPISODE Korbi M et al (starts at 1:58). Topical minoxidil-induced paresthesia. Dermatol Ther. 2022 Jan 20;e15328. Panigrahi M et al (starts at 9:37). A recent surge of doxycycline-induced pill esophagitis during the corona virus disease 2019 (COVID-19) pandemic. Indian J Gastroenterol  Jan 2022 Panigrahi M et al (starts at 14:45). A recent surge of doxycycline-induced pill esophagitis during the corona virus disease 2019 (COVID-19) pandemic. Indian J Gastroenterol  Jan 2022 Bommareddy et al (starts at 18:48). Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatol 2022 Feb 9 Ytterberg SR et al (starts at 25:13). Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: Snast I et al (starts at 37:45). Paradoxical Hypertrichosis Associated with Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-analysis  Am J Clin Dermatol 2021 Sep;22(5):615-624

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim Potpourri of Biosimilar Trials: Dr. Jonathan Kay Closing a Chapter: Interview with the 84th ACR President 2020-2021, Kathryn Dao